Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Bought by Barclays PLC

Barclays PLC boosted its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 210.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 45,110 shares of the company's stock after acquiring an additional 30,585 shares during the quarter. Barclays PLC owned 0.12% of Entrada Therapeutics worth $720,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of TRDA. Los Angeles Capital Management LLC purchased a new stake in shares of Entrada Therapeutics in the 3rd quarter worth approximately $542,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Entrada Therapeutics by 132.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company's stock worth $2,215,000 after purchasing an additional 78,953 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Entrada Therapeutics by 34.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company's stock worth $226,000 after buying an additional 3,644 shares during the period. Massachusetts Financial Services Co. MA bought a new position in Entrada Therapeutics in the 3rd quarter worth $1,109,000. Finally, State Street Corp grew its holdings in shares of Entrada Therapeutics by 5.5% in the third quarter. State Street Corp now owns 469,601 shares of the company's stock valued at $7,504,000 after purchasing an additional 24,385 shares in the last quarter. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Trading Down 0.5 %

NASDAQ TRDA traded down $0.08 on Wednesday, hitting $17.29. 116,097 shares of the company's stock traded hands, compared to its average volume of 108,163. The firm has a market capitalization of $646.99 million, a PE ratio of 10.87 and a beta of -0.18. Entrada Therapeutics, Inc. has a 1-year low of $11.35 and a 1-year high of $21.79. The firm's 50-day moving average price is $18.54 and its two-hundred day moving average price is $16.78.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on TRDA shares. Oppenheimer upped their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the company an "outperform" rating in a research report on Wednesday, November 6th. Roth Capital upgraded Entrada Therapeutics to a "strong-buy" rating in a report on Thursday, December 5th. Roth Mkm initiated coverage on shares of Entrada Therapeutics in a research report on Thursday, December 5th. They set a "buy" rating and a $29.00 price target for the company. Finally, HC Wainwright increased their price objective on Entrada Therapeutics from $18.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, November 6th.

Insiders Place Their Bets

In other news, CFO Kory James Wentworth sold 8,637 shares of Entrada Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $19.98, for a total transaction of $172,567.26. Following the transaction, the chief financial officer now owns 73,849 shares in the company, valued at $1,475,503.02. The trade was a 10.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the business's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $20.77, for a total transaction of $476,359.95. Following the completion of the sale, the insider now directly owns 4,402,849 shares in the company, valued at $91,447,173.73. This trade represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,281 shares of company stock valued at $861,999. Company insiders own 7.59% of the company's stock.

Entrada Therapeutics Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.